Literature DB >> 10533554

Cost-effectiveness of assertive community treatment for homeless persons with severe mental illness.

A F Lehman1, L Dixon, J S Hoch, B Deforge, E Kernan, R Frank.   

Abstract

BACKGROUND: Homelessness is a major public health problem among persons with severe mental illness (SMI). Cost-effective programmes that address this problem are needed. AIMS: To evaluate the cost-effectiveness of an assertive community treatment (ACT) programme for these persons in Baltimore, Maryland.
METHODS: A total of 152 homeless persons with SMI were randomly allocated to either ACT or usual services. Direct treatment costs and effectiveness, represented by days of stable housing, were assessed.
RESULTS: Compared with usual care, ACT costs were significantly lower for mental health in-patient days and mental health emergency room care, and significantly higher for mental health out-patient visits and treatment for substance misuse. ACT patients spent 31% more days in stable housing than those receiving usual care. ACT and usual services incurred $242 and $415 respectively in direct treatment costs per day of stable housing, an efficiency ratio of 0.58 in favour of ACT. Patterns of care and costs varied according to race.
CONCLUSION: ACT provides a cost-effective approach to reducing homelessness among persons with severe and persistent mental illnesses.

Entities:  

Mesh:

Year:  1999        PMID: 10533554     DOI: 10.1192/bjp.174.4.346

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  25 in total

1.  Assessments, interventions, and outcomes: who cares? Introduction.

Authors:  B H McFarland
Journal:  Community Ment Health J       Date:  2001-04

Review 2.  Intensive case management for severe mental illness.

Authors:  Marina Dieterich; Claire B Irving; Bert Park; Max Marshall
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

3.  Racial and ethnic service use disparities among homeless adults with severe mental illnesses receiving ACT.

Authors:  Marcela Horvitz-Lennon; Dongli Zhou; Sharon-Lise T Normand; Margarita Alegría; Wes K Thompson
Journal:  Psychiatr Serv       Date:  2011-06       Impact factor: 3.084

4.  African-Americans and comprehensive service use.

Authors:  Matthew T Theriot; Steven P Segal; Max J Cowsert
Journal:  Community Ment Health J       Date:  2003-06

5.  The case for stratified cost-effectiveness analysis by baseline health-related QOL: theory and sensitivity analysis.

Authors:  Joseph Schaafsma
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 6.  Economic considerations associated with assertive community treatment and supported employment for people with severe mental illness.

Authors:  Eric Latimer
Journal:  J Psychiatry Neurosci       Date:  2005-09       Impact factor: 6.186

7.  Treating homeless clients with severe mental illness and substance use disorders: costs and outcomes.

Authors:  Gary A Morse; Robert J Calsyn; W Dean Klinkenberg; Thomas W Helminiak; Nancy Wolff; Robert E Drake; Robert D Yonker; Gyanesh Lama; Matthew R Lemming; Suzanne McCudden
Journal:  Community Ment Health J       Date:  2006-08-04

8.  Planning Patient-Centered Health Homes for Medicaid Psychiatric Patients at Greatest Risk for Intensive Service Use.

Authors:  Joyce C West; Donald S Rae; Ramin Mojtabai; Farifteh F Duffy; Janet Kuramoto; Eve Moscicki; William E Narrow
Journal:  Community Ment Health J       Date:  2015-02-10

9.  Solving Homelessness from a Complex Systems Perspective: Insights for Prevention Responses.

Authors:  Patrick J Fowler; Peter S Hovmand; Katherine E Marcal; Sanmay Das
Journal:  Annu Rev Public Health       Date:  2019-01-02       Impact factor: 21.981

Review 10.  The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements.

Authors:  Lisa B Dixon; Faith Dickerson; Alan S Bellack; Melanie Bennett; Dwight Dickinson; Richard W Goldberg; Anthony Lehman; Wendy N Tenhula; Christine Calmes; Rebecca M Pasillas; Jason Peer; Julie Kreyenbuhl
Journal:  Schizophr Bull       Date:  2009-12-02       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.